Quest Diagnostics Inc. (DGX)
NYSE: DGX · Services-Medical Laboratories · Secaucus, NJ · filing with the SEC since 1996
Grade5.2
◀ Past 6.5● Present 5.5▶ Future 3.6
Who owns Quest Diagnostics Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 8.4% of Common Stock, as its SCHEDULE 13G/A filed Apr 17, 2025 says.
Directors and officers
19
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · reported falling below 5%, from 6.5% in Aug 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What DGX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Laboratory Facility
An investee · investee · invested in, named in the 10-K filed Feb 26, 2026
Haystack Oncology, Inc.
A company bought · acquisition · Jun 2023 · owns, named in the 10-K filed Feb 26, 2026
New York-Presbyterian
A company bought · acquisition · Apr 2023 · owns, named in the 10-K filed Feb 26, 2026
Acquisitions During Period
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Allina Health
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Laboratory Business of Three Physician Groups in New York
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
LifeLabs Inc.
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Ohio Health
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
80 subsidiaries in 10 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
40sales
0purchases
38sales on a scheduled plan
8people selling
$45.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Davis J. E. | CEO and President | 6 | $17.1M | 6 | 0 | $0 |
| Doherty Catherine T. | Executive Vice President | 15 | $12.4M | 15 | 0 | $0 |
| Prevoznik Michael E | SVP & General Counsel | 6 | $6.6M | 6 | 0 | $0 |
| Plewman Patrick | SVP for Diagnostic Services | 7 | $5.0M | 7 | 0 | $0 |
| Kuppusamy Karthik | SVP, Clinical Solutions | 2 | $2.2M | 1 | 0 | $0 |
| Delaney Mark E | SVP & Chief Commercial Officer | 2 | $1.9M | 2 | 0 | $0 |
| Pfeiffer Gary M | director | 1 | $300,000 | 1 | 0 | $0 |
| Gregg Vicky B | director | 1 | $200,000 | 0 | 0 | $0 |